


# 9  
Dmat  
1-16-03



Practitioner's Docket No. MPI00-282P1R (38155-20017.00)

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Glucksmann, Maria A.  
Application No.: 09/896,522 Group No.: 1645  
Filed: June 28, 2001 Examiner: To be Assigned  
For: 57658, A NOVEL HUMAN URIDINE KINASE AND USES THEREOF

**Commissioner for Patents**  
**Washington, D.C. 20231**

**RECEIVED**

NOV 20 2002

**REVOCATION OF PRIOR POWERS OF ATTORNEY**  
**AND APPOINTMENT OF NEW POWER OF ATTORNEY**

TECH CENTER 1600/2900

Dear Sir:

MILLENNIUM PHARMACEUTICALS, INC., the Assignee of the entire right, title and interest in the above-identified application by virtue of the Assignment document filed with the United States Patent and Trademark Office on January 9, 2002, at Reel 012461, Frame 0160 hereby revokes all Powers of Attorney with respect to that application heretofore granted and appoints the below listed attorneys with full power of substitution and revocation to prosecute this application and to transact all business in the Patent Office connected therewith.

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.  
**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

with sufficient postage as first class mail.

as "Express Mail Post Office to Address" Mailing Label No.

**TRANSMISSION**

transmitted by facsimile to the Patent and Trademark Office.

**Signature**

*Marian Christopher*  
(type or print name of person certifying)

Date: November 7, 2002

**\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.**

Practitioner's Docket No. MPI00-282P1R (38155-20017.00)



Scott A. Brown, Reg. No. 32,724; Susan M. Perkins, Reg. No. 36,405; Carmen Pili Ekstrom, Reg. No. 34,981; Ian R. Silverman, Reg. No. 37,443; Jean M. Silveri, Reg. No. 39,030; Allan N. Kutzenco, Reg. No. 38,945, Theodore R. Allen, Reg. No. 41,578; Kerri Pollard Schray, Reg. No. 47,066, Tracy M. Sioussat, Reg. No. 51,609; Steven A Bossone, Reg. No. 51,196; and Paul J. Paglierani, Reg. No. P-52,498

all of Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, Massachusetts 02139, United States of America.

Please direct all future correspondence to:

RECEIVED

Intellectual Property Group  
MILLENNIUM PHARMACEUTICALS, INC.  
75 Sidney Street  
Cambridge, MA 02139

NOV 20 2002

TECH CENTER 1600/2900

and direct all telephone calls to Theodore R. Allen at 617-761-6815

MILLENNIUM PHARMACEUTICALS, INC.

By: 

Typed Name: Scott A. Brown

Title: Vice President, Chief Patent Counsel

Dated: November 6, 2002